Nutritional Supplementation and Insulin Sensitivity
Study Details
Study Description
Brief Summary
Type 2 diabetes mellitus (T2DM) is a progressive disease and early intervention and prevention strategies are therefore very important. An important early hallmark in the development of T2DM is insulin resistance. Since the majority of postprandial glucose disposal occurs in skeletal muscle, improving muscle insulin sensitivity will thus have a major impact on disease prevention. Abdominally obese men and women have an increased risk to develop T2DM, and are also characterized by an impaired vascular function. This may hamper proper delivery of insulin, glucose and oxygen to muscles, thereby contributing to - and possibly causing - muscle insulin resistance. Earlier it has been shown that supplementation with L- arginine improves vascular function by improving nitric oxide (NO) bioavailability. These NO- mediated beneficial effects on vascular function may improve delivery of insulin, glucose and oxygen to the muscle tissue, thereby improving muscle insulin sensitivity and mitochondrial function. However, the doses needed of this amino acid cannot be provided by regular diets or supplements, also due to the bitter taste of L-arginine. Alternatively, smaller amounts of L- arginine with a specific combination of other nutritional components (i.e. nitrate and nitrite), which are already part of the regular diet and support alternative pathways to improve NO- mediated vascular function, may also induce beneficial effects. The investigators now hypothesize that in abdominally obese adults with impaired fasting glucose concentrations L-arginine combined with nitrate/nitrite increases muscle insulin sensitivity.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: L-arginine + Nitrate/Nitrite Subjects will receive 1 L-arginine tablet per day and drink 35 mL of beetroot juice for 8 weeks. |
Dietary Supplement: L-arginine + Nitrate / Nitrite
Longer-term supplementation (8 weeks)
|
| Placebo Comparator: Placebo Subjects will receive 1 cellulose tablet per day and drink 35 mL of nitrate/nitrite depleted beetroot juice for 8 weeks. |
Dietary Supplement: Placebo
Longer-term supplementation (8 weeks)
|
Outcome Measures
Primary Outcome Measures
- Change in insulin sensitivity [Change between 8-week placebo and 8-week intervention period]
Muscle insulin sensitivity
Secondary Outcome Measures
- Change in muscle metabolism [Change between 8-week placebo and 8-week intervention period]
Mitochondrial activity in muscle tissue
- Change in physical functioning (1) [Change between 8-week placebo and 8-week intervention period]
6 meter walking test
- Change in physical functioning (2) [Change between 8-week placebo and 8-week intervention period]
Timed up and go test
- Change in physical functioning (3) [Change between 8-week placebo and 8-week intervention period]
Handgrip strength test
- Change in physical functioning (4) [Change between 8-week placebo and 8-week intervention period]
Isokinetic muscle strength (BIODEX measurement)
- Change in vascular function (1) [Change between 8-week placebo and 8-week intervention period]
Flow-mediated vasodilation of the brachial artery
- Change in vascular function (2) [Change between 8-week placebo and 8-week intervention period]
Pulse wave analysis
- Change in vascular function (3) [Change between 8-week placebo and 8-week intervention period]
Pulse wave velocity
- Change in vascular function (4) [Change between 8-week placebo and 8-week intervention period]
Retinal microvascular calibers (Artery-to-Vein ratio)
- Change in cardiometabolic risk markers (1) [Change between 8-week placebo and 8-week intervention period]
Plasma markers for low-grade systemic inflammation (CRP)
- Change in cardiometabolic risk markers (2) [Change between 8-week placebo and 8-week intervention period]
Plasma markers for endothelial dysfunction (NOx)
- Change in cardiometabolic risk markers (3) [Change between 8-week placebo and 8-week intervention period]
24-h Systolic and Diastolic blood pressure
- Change in continuous insulin sensitivity [Change between 8-week placebo and 8-week intervention period]
36-h plasma glucose values
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged between 50-70 years
-
Men and postmenopausal (two or more years after last menstruation) women
-
Waist circumference for men 3 102 cm and for women 3 88 cm (abdominally obese)
-
Impaired fasting glucose concentrations (between 5.6 - 7.0 mmol/L in accordance with the American Diabetes Association guidelines for prediabetes) at two screening visits
-
Fasting serum total cholesterol < 8.0 mmol/L
-
Stable body weight (weight gain or loss < 3 kg in the past three months)
-
Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study
-
No difficult venipuncture as evidenced during the screening visit
-
Willingness to give up the use of antibacterial mouth wash or antibacterial toothpaste, chewing-gum and tongue-scraping during the study
Exclusion Criteria:
-
Current smoker, or smoking cessation < 12 months
-
Diabetic patients
-
Familial hypercholesterolemia
-
Abuse of drugs
-
More than 3 alcoholic consumptions per day
-
Use of dietary supplements known to interfere with the main study outcomes as judged by the principal investigators
-
Use of anticoagulant drugs or drugs to treat blood pressure, lipid/glucose metabolism
-
Use of an investigational product within another biomedical intervention trial within the previous 1-month
-
Intolerance or allergy to the ingredients of the intervention products
-
Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis
-
Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Maastricht University Medical Center | Maastricht | Limburg | Netherlands | 6229 ER |
Sponsors and Collaborators
- Maastricht University Medical Center
- Nutricia Research
Investigators
- Principal Investigator: Peter J Joris, PhD, Maastricht University Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- METC 19-085